Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
Final decisions on matters not referred to an expert advisory committee
1. New Chemical Entities - medicines for human therapeutic use
1.4 Darolutamide
Delegate's final decision
The delegate's final decision under regulation 42ZCZU of the Therapeutic Goods Regulations 1990 is to include darolutamide in Schedule 4 of the Poisons Standard as follows:
Schedule 4 - New Entry
DAROLUTAMIDE.
Index - New Entry
DAROLUTAMIDE
Schedule 4
Implementation date
1 October 2019
Reasons
The matters under subsection 52E(1) of the Therapeutic Goods Act 1989 considered relevant by the delegate for the decision include:
- the risks and benefits of the use of a substance:
- The risks and benefits of darolutamide require the involvement of a medical practitioner experienced in the diagnosis and treatment of the condition.
- the purposes for which a substance is to be used and the extent of use of a substance:
- The use of darolutamide should be managed by a medical practitioner experienced in the diagnosis and treatment of the condition.
- the toxicity of a substance:
- The toxicity of darolutamide requires ongoing clinical review by a medical practitioner.
- the dosage, formulation, labelling, packaging and presentation of a substance:
- Ongoing clinical monitoring is required to determine whether dose interruptions and/or reductions are required.
- the potential for abuse of a substance:
- Nil.
- any other matters that the Secretary considers necessary to protect public health:
- Nil.
Scheduling proposal
The delegate of the Secretary proposed to amend the Poisons Standard with respect to darolutamide, a new chemical entity (NCE) for a human therapeutic medicine.
Scheduling status
Darolutamide is not specifically scheduled and is not captured by any entry in the Poisons Standard.
Delegate's considerations
- Advice on the place in therapy of this NCE;
- Scheduling Policy Framework (SPF 2018); and
- Section 52E(1) of the Therapeutic Goods Act 1989 in particular: (a) the risks and benefits of the use of a substance; (b) the purposes for which a substance is to be used and the extent of use of a substance; (c) the toxicity of a substance; and (d) the dosage, formulation, labelling, packaging and presentation of a substance.